Literature DB >> 15592778

Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells.

Yoko Karasawa1, Shigekuni Okisaka.   

Abstract

PURPOSE: Exposure of Y79 cells, a retinoblastoma cell line, to sodium butyrate, a histone deacetylase inhibitor, induces neuronlike morphological changes and apoptosis. To determine whether the effect of butyrate results from an inhibition of histone deacetylation, we examined the morphological changes, cell viability, and histone acetylation levels of Y79 cells induced by butyrate and trichostatin A (TSA), a specific inhibitor of histone deacetylases.
METHODS: Y79 cells cultured in a synthetic medium were exposed to butyrate or TSA, and the morphological changes and cell viability were followed. Actinomycin D was used to determine whether the morphological changes were transcription-dependent. The level of acetylated histone was determined by Western blotting and immunocytochemistry.
RESULTS: Butyrate and TSA induced morphological changes and apoptosis of Y79 retinoblastoma cells in a dose-dependent manner. The morphological changes were sustained and reversible with butyrate but were transient with TSA. Actinomycin D completely inhibited the morphological changes induced by butyrate and TSA. The elevation of histone H3 levels was sustained and reversible in butyrate but transient in TSA. The change in histone H3 acetylation levels preceded the morphological changes and apoptosis.
CONCLUSION: The induction of morphological changes by butyrate results from an inhibition of histone deacetylation and transcription.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592778     DOI: 10.1007/s10384-004-0122-7

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  8 in total

1.  Histone deacetylase inhibitors suppress transdifferentiation of gonadotrophs to prolactin cells and proliferation of prolactin cells induced by diethylstilbestrol in male mouse pituitary.

Authors:  Nandar Tun; Yasuaki Shibata; Myat Thu Soe; Myo Win Htun; Takehiko Koji
Journal:  Histochem Cell Biol       Date:  2018-12-03       Impact factor: 4.304

2.  Cotylenin A inhibits cell proliferation and induces apoptosis and PAX6 mRNA transcripts in retinoblastoma cell lines.

Authors:  Yoshiko Kashiwagi; Nobuo Kato; Takeshi Sassa; Koichi Nishitsuka; Teiko Yamamoto; Hiroshi Takamura; Hidetoshi Yamashita
Journal:  Mol Vis       Date:  2010-06-04       Impact factor: 2.367

3.  Histone deacetylase inhibitor induces the expression of select epithelial genes in mouse utricle sensory epithelia-derived progenitor cells.

Authors:  Zhengqing Hu; Jue Wang
Journal:  Cell Reprogram       Date:  2014-06-19       Impact factor: 1.987

4.  Functional and molecular characterization of rod-like cells from retinal stem cells derived from the adult ciliary epithelium.

Authors:  Gian Carlo Demontis; Claudia Aruta; Antonella Comitato; Anna De Marzo; Valeria Marigo
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

Review 5.  Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives.

Authors:  Hua Zhang; Xufeng Dai; Yan Qi; Ying He; Wei Du; Ji-Jing Pang
Journal:  J Ophthalmol       Date:  2015-06-02       Impact factor: 1.909

6.  Regulation of Opsin Gene Expression by DNA Methylation and Histone Acetylation.

Authors:  Jin Song; Julia A VanBuskirk; Shannath L Merbs
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

7.  Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells.

Authors:  Douglas M Guimarães; Luciana O Almeida; Manoela D Martins; Kristy A Warner; Alan R S Silva; Pablo A Vargas; Fabio D Nunes; Cristiane H Squarize; Jacques E Nör; Rogerio M Castilho
Journal:  Oncotarget       Date:  2016-07-05

8.  UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.

Authors:  Jong Kyong Kim; Guangyan Kan; Yu Mao; Zhixuan Wu; Xionghong Tan; Heng He; Chunsik Lee
Journal:  Mol Oncol       Date:  2019-12-13       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.